- EMVision Medical Devices (EMV) confirms the first two clinical sites for upcoming trials of its brain scanner product
- The company selected the Royal Melbourne Hospital in Victoria and Liverpool Hospital in NSW due to their specialisation in diagnosing and managing acute stroke patients
- EMVision progresses in-principle agreements with the two hospitals detailing how the studies will be conducted at these selected sites
- In addition, EMV appoints Avania Clinical to support the upcoming multi-centre study
- Shares in EMVision last traded at $1.75 on July 11
EMVision Medical Devices (EMV) has confirmed the Royal Melbourne Hospital and the Liverpool Hospital in NSW as the first clinical sites for upcoming trials of its brain scanner product.
The company said it had progressed in-principle agreements with the two “centres of excellence for stroke care” detailing how the studies would be conducted at the selected sites.
The company’s brain scanner technology aims to monitor for strokes and diagnose other conditions.
The two clinical sites were selected due to their specialisation in diagnosing and managing acute stroke patients.
EMVision CEO Ron Weinberger said the company was looking forward to collaborating with the trial sites as it moved into the clinical trials, with studies targeted to begin before the end of September.
“This is a key milestone in the development of our novel portable brain scanner as we seek to fulfil our mission of improving stroke patient outcomes,” Dr Weinberger said.
The company said it would announce additional trial sites progressively and planned to release further information on its clinical trial plan “shortly”.
In addition to the two clinical sites, EMV has appointed Avania Clinical to support the upcoming multi-centre study.
Avania specialises in managing medical device clinical studies and supporting products from the first-in-human phase of a trial through to the post-market phase.
Shares in EMVision last traded at $1.75 on July 11.